CytomX Therapeutics EPS - Earnings per Share 2014-2022 | CTMX
CytomX Therapeutics eps - earnings per share from 2014 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| CytomX Therapeutics Annual EPS |
| 2021 |
$-1.30 |
| 2020 |
$-0.71 |
| 2019 |
$-2.26 |
| 2018 |
$-2.03 |
| 2017 |
$-1.16 |
| 2016 |
$-1.63 |
| 2015 |
$-4.90 |
| 2014 |
$-35.25 |
| 2013 |
$-24.46 |
| CytomX Therapeutics Quarterly EPS |
| 2022-06-30 |
$-0.37 |
| 2022-03-31 |
$-0.37 |
| 2021-12-31 |
$-0.39 |
| 2021-09-30 |
$-0.35 |
| 2021-06-30 |
$-0.30 |
| 2021-03-31 |
$-0.26 |
| 2020-12-31 |
$-0.31 |
| 2020-09-30 |
$-0.32 |
| 2020-06-30 |
$-0.34 |
| 2020-03-31 |
$0.26 |
| 2019-12-31 |
$-0.79 |
| 2019-09-30 |
$-0.52 |
| 2019-06-30 |
$-0.64 |
| 2019-03-31 |
$-0.31 |
| 2018-12-31 |
$-0.75 |
| 2018-09-30 |
$-0.53 |
| 2018-06-30 |
$-0.35 |
| 2018-03-31 |
$-0.40 |
| 2017-12-31 |
$0.04 |
| 2017-09-30 |
$-0.28 |
| 2017-06-30 |
$-0.69 |
| 2017-03-31 |
$-0.23 |
| 2016-12-31 |
$-0.40 |
| 2016-09-30 |
$-0.40 |
| 2016-06-30 |
$-0.39 |
| 2016-03-31 |
$-0.44 |
| 2015-12-31 |
$24.59 |
| 2015-09-30 |
$-14.26 |
| 2015-06-30 |
$-7.56 |
| 2015-03-31 |
$-7.67 |
| 2014-12-31 |
$0.00 |
| 2014-09-30 |
$-4.86 |
| 2013-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.110B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
